DXCM
DexCom, Inc.
Set alert
82.29 USD +2.36 +2.95%
79.79 Day range 85.25
54.84 52-week range 92.34
- YTD
- +23.99%
- 1 year
- +20.66%
- Open
- 81.52
- Prev close
- 79.93
- Mkt cap
- 31.05B
- Vol
- 8.64M
- Avg vol
- 4.56M
- EPS
- 2.52
- P/E
- 32.65
- Div yield
- 0.00%
More statistics
- Low
- 79.79
- High
- 85.25
- Forward P/E
- 26.27
- Beta
- 1.48
- Short ratio
- 3.91
- Inst. own
- 106.54%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 11, 2027
- 50-d avg
- 85.98
- 200-d avg
- 74.50
- 1y target
- 96.19
Key statistics
- Market cap
- 31.02B
- Enterprise value
- 29.61B
- Trailing P/E
- 32.62
- Forward P/E
- 26.27
- PEG ratio
- 1.32
- Price / sales
- 6.24
- Price / book
- 11.52
- EPS (TTM)
- 2.52
- Beta
- 1.48
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 20.12%
- Revenue (TTM)
- 4.97B
- Revenue growth
- 13.10%
- Free cash flow
- 1.02B
- Total cash
- 1.95B
- Total debt
- 1.40B
- Return on equity
- 38.49%
- Shares outstanding
- 377.36M
- Short % of float
- 4.80%
- 50-day average
- 85.98
- 200-day average
- 74.50
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 96.19 +16.9% upside
Now 82.29
- Target (low)
- 79.00
- Target (mean)
- 96.19
- Target (high)
- 115.00
Ratings (0m) 29 26 buy · 3 hold · 0 sell
- Strong buy4
- Buy22
- Hold3
- Sell0
- Strong sell0
Next earnings
Feb 11, 2027
Expected Feb 11, 2027. Consensus EPS estimate 0.73633.
Financials — quick view
DXCM Revenue — quarterly 1.34B
DXCM Net income — quarterly 275.10M
DXCM EPS — quarterly 0.73
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 11, 2027 | Dec 30, 2026 | 0.73 | — | — | — |
| Oct 29, 2026 | Sep 30, 2026 | 0.675 | 0.73 | +0.05 | +8.15% |
| Jul 30, 2026 | Jun 30, 2026 | 0.611 | 0.70 | +0.09 | +14.57% |
| Apr 30, 2026 | Mar 31, 2026 | 0.4656 | 0.56 | +0.09 | +20.27% |
| Feb 12, 2026 | Dec 31, 2025 | 0.65 | 0.68 | +0.03 | +4.62% |
| Oct 30, 2025 | Sep 30, 2025 | 0.576 | 0.61 | +0.03 | +5.90% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 30, 2026 | Barclays | main | Overweight | Overweight |
| Oct 30, 2026 | StoneX | main | Buy | Buy |
| Oct 12, 2026 | BTIG | main | Buy | Buy |
| Oct 7, 2026 | Barclays | init | — | Overweight |
| Oct 1, 2026 | RBC Capital | main | Outperform | Outperform |
| Sep 18, 2026 | Truist Securities | main | Buy | Buy |
About DexCom, Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- dexcom.com
News
- Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $97
- JP Morgan Maintains Neutral on DexCom, Raises Price Target to $85
- DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise
- Barclays Maintains Overweight on DexCom, Raises Price Target to $120
- StoneX Maintains Buy on DexCom, Raises Price Target to $93
- DexCom, Inc. (DXCM) Q3 2026 Earnings Call Transcript
- What DexCom (DXCM) Said on Its Q3 Earnings Call
- DexCom (DXCM) Surpasses Q3 Earnings and Revenue Estimates
- DexCom Q3 2026 Earnings Call Transcript
- DexCom Q3 2026 Earnings Call Transcript
Your note
Sign in to keep a note on DXCM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALTMAN STEVEN R | Director | Stock Award(Grant) | May 27, 2026 | 69,232 |
| BROWN MICHAEL JON | Officer | Sale | Oct 14, 2026 | 98,185 |
| COLEMAN JON | Officer | Sale | Jun 3, 2026 | 95,450 |
| COLLINS RICHARD ALEXANDER | Director | Stock Award(Grant) | May 27, 2026 | 45,767 |
| FOLETTA MARK G | Director | Sale | Aug 2, 2026 | 0 |
| LEACH JACOB STEVEN | Chief Executive Officer | Stock Award(Grant) | Mar 5, 2026 | 469,106 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 10.13% | 38,244,137 | 3.14B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.68% | 25,209,752 | 2.07B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.21% | 19,656,540 | 1.62B | Jun 29, 2026 |
| State Street Corporation | 4.87% | 18,380,806 | 1.51B | Jun 29, 2026 |
| Invesco Ltd. | 4.05% | 15,288,133 | 1.26B | Jun 29, 2026 |
| BAILLIE GIFFORD & CO | 3.92% | 14,801,590 | 1.22B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.25% | 12,250,468 | 1.01B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.65% | 10,000,154 | 822.01M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund | 2.22% | 8,360,947 | 687.27M | Jun 29, 2026 |
| Invesco QQQ Trust, Series 1 | 2.09% | 7,879,739 | 647.71M | Sep 29, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 1.43% | 5,384,037 | 442.57M | Jul 30, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.33% | 5,008,979 | 411.74M | Aug 30, 2026 |